Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency

References

• Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, et al. 1993. Clues to the pathogenesis of familial colorectal cancer. Science. 260(5109):812–16.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 114(8):1537–44.
   PubMed Web of Science ®Google Scholar
• Begum R, Martin SA. 2016. Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment. DNA Repair (Amst). 38:135–39.
   PubMed Web of Science ®Google Scholar
• Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, Kumar M, Jones S, Rees B, Williams G, et al. 2012. Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut. 61(8):1163–71.
   PubMed Web of Science ®Google Scholar
• Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. 2016. Molecular Pathways: targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 22(21):5183–88.
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 56(5):739–45.
   PubMed Web of Science ®Google Scholar
• Boland PM, Yurgelun MB, Boland CR. 2018. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 68(3):217–31.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, et al. 2017. TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 7(1):e1371399.
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, et al. 2015. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 125(5):2046–58.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity. 39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS. 2011. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 6(9):e24671.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, Jemal A, Yu X, He J. 2016. Cancer statistics in China, 2015. CA Cancer J Clin. 66(2):115–32.
   PubMed Web of Science ®Google Scholar
• Clark AJ, Barnetson R, Farrington SM, Dunlop MG. 2004. Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer. 3(2):85–91.
   PubMedGoogle Scholar
• Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407):330–37. doi:10.1038/nature11252
   PubMed Web of Science ®Google Scholar
• de Vos Tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G, Slors JF, Nagengast FM, Kleibeuker JH, Vasen HF. 2003. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 52(12):1752–55.
   PubMed Web of Science ®Google Scholar
• Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, Kurtulus S, Kassam N, Sobel RA, Fukumura D, et al. 2018. Functional Anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 200(8):3000–07.
   PubMed Web of Science ®Google Scholar
• Dosset M, Vargas TR, Lagrange A, Boidot R, Vegran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-Joseph E, et al. 2018. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 7(6):e1433981.
   PubMed Web of Science ®Google Scholar
• Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM. 2011. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 9(4):340–43.
   PubMed Web of Science ®Google Scholar
• Gao J, Zheng Q, Xin N, Wang W, Zhao C. 2017. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 108(10):1934–38.
   PubMed Web of Science ®Google Scholar
• Graham C, Hewitson R, Pagliuca A, Benjamin R. 2018. Cancer immunotherapy with CAR-T cells - behold the future. Clin Med (Lond). 18(4):324–28.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, et al. 2007. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 117(11):3383–92.
   PubMed Web of Science ®Google Scholar
• He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W, et al. 2017. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 77(22):6375–88.
   PubMed Web of Science ®Google Scholar
• Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S. 2004. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol. 16(2):135–43.
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, et al. 2018. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 7(8):e1466769.
   PubMed Web of Science ®Google Scholar
• Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. 1993. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 363(6429):558–61.
   PubMed Web of Science ®Google Scholar
• Jiricny J. 2006. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 7(5):335–46.
   PubMed Web of Science ®Google Scholar
• Johdi NA, Ait-Tahar K, Sagap I, Jamal R. 2017. Molecular signatures of human regulatory T Cells in colorectal cancer and polyps. Front Immunol. 8:620.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. 2014. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 26(6):923–37.
   PubMed Web of Science ®Google Scholar
• Kim S, Roh J, Park C. 2016. Immunohistochemistry for pathologists: protocols, pitfalls, and tips. J Pathol Transl Med. 50(6):411–18.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC. 2015. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 125(11):4053–62.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372(26):2509–20.
   PubMed Web of Science ®Google Scholar
• Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, Johnston J, Hammond A, Bontadelli K, Ardourel D, et al. 2011. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 41(4):902–15.
   PubMed Web of Science ®Google Scholar
• Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, et al. 2014. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem. 289(25):17647–57.
   PubMed Web of Science ®Google Scholar
• Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S, Cosmi L, Maggi L, et al. 2011. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 107(9):1500–06.
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL. 2017. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, et al. 2012. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 308(15):1555–65.
   PubMed Web of Science ®Google Scholar
• Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E. 2015. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 33(31):3544–49.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. 2006. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 12(10):3064–69.
   PubMed Web of Science ®Google Scholar
• O’Kane GM, Ryan E, McVeigh TP, Creavin B, Hyland JM, O’Donoghue DP, Keegan D, Geraghty R, Flannery D, Nolan C, et al. 2017. Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers. Cancer Med. 6(6):1465–72.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. 2018. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36(8):773–79.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. 2017. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18(9):1182–91.
   PubMed Web of Science ®Google Scholar
• Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, Baron JA, Giles GG, Leggett BA, Winship I, et al. 2011. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 60(7):950–57.
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH, Blazar BR. 2009. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 30(5):656–65.
   PubMed Web of Science ®Google Scholar
• Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al. 2016. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22(6):679–84.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207(10):2187–94.
   PubMed Web of Science ®Google Scholar
• Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, Xi X. 2011. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 129(6):1373–81.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. 2017. Colorectal cancer statistics, 2017. CA Cancer J Clin. 67(3):177–93.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. CA Cancer J Clin. 68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al. 2009. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 106(42):17858–63.
   PubMed Web of Science ®Google Scholar
• Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L, Wiesmann C, Bazan JF, Eaton DL, Grogan JL. 2012. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A. 109(14):5399–404.
   PubMed Web of Science ®Google Scholar
• Strand M, Prolla TA, Liskay RM, Petes TD. 1993. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature. 365(6443):274–76.
   PubMed Web of Science ®Google Scholar
• Sun X, Liu S, Wang D, Zhang Y, Li W, Guo Y, Zhang H, Suo J. 2017. Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling. Oncotarget. 8(9):15168–81.
   PubMedGoogle Scholar
• Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. 2017. Intratumoral FoxP3(+)Helios(+) Regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer. Front Immunol. 8:619.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. 2018. T Cell Dysfunction in Cancer. Cancer Cell. 33(4):547–62.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. 2013. Cancer genome landscapes. Science. 339(6127):1546–58.
   PubMed Web of Science ®Google Scholar
• Wang M, Yin B, Wang HY, Wang RF. 2014. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 6(12):1265–78.
   PubMed Web of Science ®Google Scholar
• Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, Young GP, Lipton L, Winship I, Boussioutas A, et al. 2013. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol. 20(6):1829–36.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu W, Qiu S, Xiong S. 2010. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 135(3):466–75.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. 2018. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 19(7):723–32.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Jiang X, Li Q. 2019. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 12(1):54.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. 2009. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 125(7):1640–48.
   PubMed Web of Science ®Google Scholar